APPENDIX 1: SAMPLE REDACTED PAGE

One such sample page containing manufacturing and testing information is shown below:


(b) (4)

Report VR-MVR-10083 describes the method validation for the SARS-CoV-2 mNG NT assay conducted at Pfizer Hackensack. The validation results are summarized below:

(b) (4)

Reviewer's Comments

Assay specificity was assessed in the evaluation of the limit of detection. This validation study at Pfizer Hackensack involved assessing (b) (4)

119

In the sample immediately above, a tremendous amount of critically important information from the official FDA Chemistry Manufacturing and Controls report[1] (ie, how its manufactured and tested for quality assurance) including FDA critique/commentary are redacted to the point that nobody other than the FDA or manufacturers could ever test the quality or fully know the ingredients in COVID-19 mRNA shots. In this 127-page document, about half of the pages were 100% redacted and the remaining about 30% redacted making the entire document unintelligible, such as the one sample page shown above. Those FDA (b)(4) redactions[2] specified detailed redactions used to "*protect[s] trade secrets and confidential commercial or financial information*." But is it really appropriate to label COVID-19 mRNA injections "commercial" if the research/development/product was funded with hundreds of millions of *taxpayer dollars*?[3]

---

[1]U.S. Food and Drug Administration, Chemistry Manufacturing and Controls Review Memorandum, August 21. 2021, p. 119, https://web.archive.org/web/20240105112728/https://pink.citeline.com/-/media/supporting-documents/pink-sheet/2022/05/cmc-review-memo--august-21-2021--comirnaty.pdf?rev=9f926c57796f427eb7da8ccf8d5fdf53&hash=26A228D0AA3A554A05096716961D817E.

[2]U.S. Food and Drug Administration, Freedom of Information, https://www.fda.gov/regulatory-information/freedom-information/foi-information.

[3]Niall McCarthy, "The Top Recipients of Covid-19 R&D Funding," Statista, May 6, 2021, https://www.statista.com/chart/24806/main-recipients-of-covid-19-investments/.

In fair defense of the FDA, it is unclear if those documents were hyper-redacted by the FDA or if there was some codicil within the Public Readiness and Emergency Preparedness Act (PREP Act) or something with the Emergency Use Authorization (EUA) authority or liability protections for pandemic and epidemic products in the Public Health Services Act that grants manufacturers the ability to redact technical data as they see fit, despite making technical documents impossible to decipher to anyone other than the FDA or manufacturers.

Obviously, it is problematic to attempt to assess the safety of any product without being able to know and compare the exact quality, quantity, structure to the known ingredient list of the product. One study has shown a widely differing adverse event profiles relative to lot/batches, potentially meaning that variable product quality could play an important role in the safety of COVID mRNA injections. One such example is a Danish safety study[4] which detailed a highly deviant pattern of adverse event reports from COVID mRNA injections based on different batches, as correlated with the Danish adverse event reporting system.

[4]Max Schmeling, Vibeke Manniche, Peter Riis Hansen, "Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine," European Journal of Clinical Investigation, Volume 53, Issue 8, August 2023, https://onlinelibrary.wiley.com/doi/10.1111/eci.13998.